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ABSTRACT Thalidomide is known to in-
duce oxidative stress, but mechanisms have not
been described through which oxidative stress
could contribute to thalidomide-induced terata.
Oxidative stress modulates intracellular gluta-
thione (GSH) and redox status and can perturb
redox-sensitive processes, such as transcription
factor activation and/or binding. Nuclear factor-
kappa B (NF-B), a redox-sensitive transcription
factor involved in limb outgrowth, may be mod-
ulated by thalidomide-induced redox shifts. Tha-
lidomide-resistant Sprague-Dawley rat embryos
(gestation day [GD] 13) treated with thalidomide
in utero showed no changes in GSH distribution
in the limb but thalidomide-sensitive New Zea-
land White rabbit embryos (GD 12) showed selec-
tive GSH depletion in the limb bud progress zone
(PZ). NF-B and regulatory genes that initiate
and maintain limb outgrowth and development,
such as Twist and Fgf-10, are selectively ex-
pressed in the PZ. Green fluorescent protein
(GFP) reporter vectors containing NF-B bind-
ing promoter sites were transfected into both rat
and rabbit limb bud cells (LBCs). Treatment with
thalidomide caused a preferential decrease in
GFP expression in rabbit LBCs but not in rat
LBCs. N-acetylcysteine and -N-t-phenylbutyl ni-
trone (PBN), a free radical trapping agent, res-
cued GFP expression in thalidomide-treated cul-
tures compared with cultures that received
thalidomide only. In situ hybridization showed a
preferential decrease in Twist, Fgf-8, and Fgf-10
expression after thalidomide treatment (400
mg/kg per day) in rabbit embryos. Expression in
rat embryos was not affected. Intravenous co-
treatment with PBN and thalidomide (gavage) in
rabbits restored normal patterns and localiza-
tion of Twist, Fgf-8, and Fgf-10 expression. These
findings show that NF-B binding is diminished
due to selective thalidomide-induced redox
changes in the rabbit, resulting in the significant
attenuation of expression of genes necessary for
limb outgrowth. © 2002 Wiley-Liss, Inc.
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INTRODUCTION
Mechanisms underlying the production of functional
and anatomic developmental abnormalities are diffi-
cult to describe due to the combined effects of chemical
and environmental factors upon an already complex
developmental program. The etiologies of most dis-
eases with early developmental origins are mostly un-
known, but many are postulated to be multifactorial,
involving both genetic and environmental components.
A definition of the biological interface between these
genetic events and the suspected environmental fac-
tors has been elusive. An important recent advance in
this area has been the recognition that changes in the
balance of oxidizing and reducing equivalents (redox
status) within the cell can have profound regulatory
consequences in terms of the control of cell prolifera-
tion, differentiation, apoptosis, and several functional/
biochemical pathways. Signal transduction compo-
nents, kinases, nuclear transcription factors, receptors,
and transporters have all been shown to be sensitive to
even relatively small changes in the intracellular redox
potential. Critical to the discussion of development and
disease in terms of the environmental interface is the
well established fact that a common consequence of
many environmental and chemical insults is a shift in
the intracellular redox environment, particularly when
the insult results in the generation of free radicals
and/or excessive reactive oxygen species (ROS). These
events are due primarily to the oxidation of soluble and
protein sulfhydryls such as glutathione (GSH) and the
free cysteine residues of proteins (protein-glutathione
mixed disulfides; prot-SSG) to protect vital cellular
components and restore reducing conditions. The GSH
redox status in developing cells may be the critical
environmental sensor that mediates the exchange of
regulator information between the environment and
the genome. Our recent and ongoing characterizations
of the effects of environmental and therapeutic chemi-
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cals on the embryonic GSH status have led to the
suggestion that temporal, spatial, and species differ-
ences in sensitivity to chemical exposure is related to a
cell’s inherent ability to maintain and regulate its in-
tracellular GSH and redox status within a range that is
permissive for normal signaling and regulation (Han-
sen et al., 2001a). Several human and animal terato-
gens are known to produce free radicals or other
reactive chemical intermediates as part of their bio-
transformation and mechanism of teratogenesis. We
support the concept that the resulting disruption of the
normal redox environment causes the misregulation of
gene expression, contributing to malformation and dis-
ease. Previous work has demonstrated that the human
teratogen thalidomide causes oxidative stress and ROS
production (Hansen et al., 1999; Parman et al., 1999;
Sauer et al., 2000). This communication reports how
thalidomide, through its ability to alter redox status,
exerts selective changes in the regulation of limb out-
growth in the sensitive rabbit but not the resistant rat
by misregulation of gene expression mediated through
the redox-sensitive transcription factor, nuclear factor
kappa B (NF-B).
Numerous stimuli, including conditions of oxidative
stress and ROS, can cause the dissociation of the cyto-
solic NF-B/IB complex, allowing NF-B to translo-
cate into the nucleus where it binds to its DNA recog-
nition sequence (5GGGACTTTCC3) and initiates
gene transcription. NF-B binding to DNA is depen-
dent on the reduced state of a critical cysteine residue
(cysteine62) on the p50 subunit. Site-directed muta-
genic substitution of cysteine62 with serine reduces the
effectiveness of DNA binding and renders NF-B inac-
tive and insensitive to redox regulation (Matthews et
al., 1992; Hayashi et al., 1993; Mitomo et al., 1994).
The NF-B regulation of gene expression in the limb
bud has been described previously by Bushdid et al.
(1998) and Kanegae et al. (1998), who concluded that
normal NF-B signaling is critical for limb bud out-
growth and development.
Establishment of a feedback loop between signals
from the apical ectodermal ridge (AER) and signals
from the progress zone (PZ), highly proliferative cells
underlying the AER, is required to initiate and main-
tain limb outgrowth. Perturbations in normal signaling
may result in the loss of proper gene activation and
result in limb reduction. I-B mutant experiments that
decrease the amount of translocated NF-B available
for DNA binding caused the decreased expression of
critical genes in the PZ and indirectly caused the de-
creased expression of genes in the AER and zone of
polarizing activity (ZPA). Twist expression in the PZ,
Fgf-8 expression in the AER, and Shh in the ZPA were
all affected by the disruption of normal NF-B activi-
ties (Bushdid et al., 1998; Kanegae et al., 1998).
The TWIST gene product has been implicated in
human and animal limb development. Mutations in
this gene result in Saethre-Chotzen syndrome, which is
characterized by craniofacial and limb malformations
(Bourgeois et al., 1998; Paznekas et al., 1998; Rice et
al., 2000). The Twist protein contains a basic helix-
loop-helix motif, suggesting that it may act as a tran-
scription factor. It is expressed in the limb in the area
of the PZ and stimulates the expression of certain FGF
receptors, namely Fgfr-1 and Fgfr-2 (Paznekas et al.,
1998; Rice et al., 2000). Fgfr-2-deficient mice have been
shown to have limb defects in which the affected limb
bears a striking resemblance to thalidomide-induced
limb malformations (Xu et al., 1998).
Fibroblast growth factor 10 (Fgf-10), like Twist, is
expressed in the limb bud PZ. Fgf-10 has been shown to
diffuse from the PZ and directly promote the expres-
sion of Fgf-8, which, in the limb, is found only in the
AER (Ohuchi et al., 1997). This interaction between
Fgf-10 in the progress zone and Fgf-8 in the AER is
considered crucial for normal limb outgrowth (Crossley
et al., 1996). The removal of the AER stunts limb out-
growth due to the loss of Fgf-8 signaling (Summerbell,
1974), but the addition of exogenous Fgf-8 restores
outgrowth (Vogel et al., 1996). Similarly, Fgf-10-defi-
cient mice had no evidence of the formation of any limb
elements (Kato and Sekine, 1999). The feedback loop
that occurs between Fgf-10 and Fgf-8 is mediated in
part by the Twist-regulated expression of an FGF re-
ceptor, Fgfr-2 (Xu et al., 1998). Perturbation of the
interaction between Fgf-10 and Fgf-8 and compounded
by decreased Twist expression results in faulty limb
outgrowth, and amelia ensues. Besides phocomelia,
amelia was one of the more common thalidomide-in-
duced terata (Fabro, 1981).
Although our efforts in this project will concentrate
on redox misregulation of NF-B–initiated pathways in
the PZ and AER in the developing limb, thalidomide
experiments are designed to specifically address both
NF-B/DNA binding and the expression of NF-B–de-
pendent genes. Redox misregulation of NF-B as a
mechanism of teratogenesis may not only serve as a
model for thalidomide teratogenicity but may also pro-
vide a general paradigm for the study of other terato-
gens that cause oxidative stress.
RESULTS
Mercury Orange Histochemistry
Mercury orange (HgO) is a stain that permits the
visualization of small biothiols, namely GSH and cys-
teine, which both serve as intracellular reducing equiv-
alents and are important contributors to redox status.
Loss of staining is indicative of a loss of GSH and
suggests oxidative stress. Limb cryosections stained
with HgO provide spatial information of thalidomide-
induced oxidative stress in treated and control limbs,
but not between species.
HgO staining of control rat limbs showed a relatively
even distribution of thiols throughout the limb (Fig. 1).
Treatment with 300 mg of thalidomide/kg per day in
utero did not produce any significant differences in rat
embryonic limbs; a uniformity of mercury orange stain-
ing was maintained.
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Thiols were evenly distributed throughout control
rabbit limbs (Fig. 1), but limbs from rabbit embryos
treated with 70 mg of thalidomide/kg/day showed a
specific decrease in mercury orange staining in the
limb bud PZ. Thiol status in the AER was unaffected in
both rat and rabbit limbs after thalidomide treatment.
pNF-B-d2EGFP Transfection
Because of the role of NF-B as a critical regulator of
limb development, the use of a reporter vector provides
additional information on the effects of thalidomide
directly on the DNA binding efficiency in intact LBCs.
Furthermore, using an in vitro approach allows for
treatment with specific pharmacologic agents that af-
fect redox status in different ways. N-acetylcysteine
(NAC) is a cysteine precursor that, during periods of
oxidative stress, provides the rate-limiting amino acid
required for de novo GSH synthesis. Glutathione reple-
tion restores intracellular redox status to normal re-
ducing conditions. The addition of -phenyl-N-t-bu-
tylnitrone (PBN), a free radical trapping agent,
removes ROS before redox status is altered. Thus, the
use of NAC and PBN promotes the restoration of nor-
mal intercellular redox status, albeit by different mech-
anisms.
Rat and rabbit LBCs transfected with pNF-B-
d2EGFP treated with diamide exhibited significantly
decreased GFP expression: 86% (2.1%) and 52%
(10.8%) of control fluorescence, respectively (Fig. 2).
Thalidomide treatment of rat limb bud cells trans-
fected with pNF-B-d2EGFP did not result in fluores-
cence differences compared with control cultures (Fig.
2). However, rabbit LBCs transfected with pNF-B-
d2EGFP and treated with 100 M thalidomide exhib-
ited a significant decrease in GFP expression measur-
ing 24% (2.8%) of the fluorescence seen in control
cultures.
Pretreatment with NAC did not affect GFP expres-
sion in rat LBCs transfected with pNF-B-d2EGFP
(Fig. 2). However, thalidomide treatment effects on
GFP expression in rabbit LBCs transfected with pNF-
B-d2EGFP could be partially rescued with NAC pre-
treatment. Expression of GFP was significantly in-
creased with NAC treatment to 68% (8.9%) of control
fluorescence compared with transfected cells receiving
thalidomide only (24% of control values).
Pretreatment with the free radical trapping agent
PBN had little effect on rat limb bud cells but proved
very protective in rabbit limb bud cells. GFP fluores-
cence was increased from 24% in rabbit LBCs treated
with thalidomide only to 77% (10.2%) in rabbit LBCs
treated with both thalidomide and PBN (Fig. 2). Al-
though PBN treatments were slightly more protective
than NAC, differences were not significant.
Whole-Mount In Situ Hybridization
Comparison of gene expression between species was
performed in situ for genes that have been shown pre-
viously to be affected by the disruption of normal
NF-B activity. Specifically, Fgf-10, Twist, and Fgf-8
were evaluated in embryos from early organization of
limb outgrowth (GD 11.5 rat, GD 10 rabbit) to later
stages of limb development (GD 13 rat; GD 11 and 12
rabbit).
Fig. 1. Mercury orange (HgO) -stained rat (gestation day [GD] 13)
and rabbit (GD 12) limbs treated with 300 and 70 mg thalidomide/kg per
day, respectively. Black arrows denote the region of the progress zone
(PZ); and white arrows denote the area of the apical ectodermal ridge
(AER). Rat thalidomide-treated limb buds did not show any relevant
decrease in HgO staining compared with control rat limb buds, suggest-
ing little or no oxidative stress. In thalidomide-treated rabbit limb buds,
there is a clear decrease in HgO fluorescence in the PZ but not the
overlying AER compared with control rabbit limb buds, indicating a de-
pletion of PZ glutathione and regional oxidative stress.
Fig. 2. pNF-B-d2EGFP–transfected rat and rabbit limb bud cells
show a decrease in GFP fluorescence with thalidomide treatment but are
rescued by redox modulating agents, N-acetylcysteine (NAC) and -phe-
nyl-N-t-butylnitrone (PBN). Diamide, an oxidant and known inhibitor NF-
B/DNA binding, acted as a positive control. Data are represented as
percentage of control GFP expression: hatched bars denote transfected
rat limb bud cells, and open bars denote transfected rabbit limb bud cells.
Asterisks (*) denote a statistically significant (0.05) difference from
control GFP expression. Crosses (†) represent a statistically significant
(0.05) difference between transfected cells treated with thalidomide
(THAL) and thalidomide  NAC or PBN. TPA, tetradecanoylphorbol
acetate.
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Localization and expression of Fgf-10 was found
throughout the PZ of control rat embryos on GD 11.5
and 13, the normal region of Fgf-10 expression in the
limb (Figs. 3, 4). Fgf-10 expression in GD 11.5 rat
embryonic limbs was spread throughout the presump-
tive limb bud field. More-developed limb buds from GD
13 rat embryos showed a more easily detectable pat-
tern of Fgf-10 expression localized in the PZ (Fig. 4).
Basically, the localization and expression of Fgf-10 in
the rat embryonic limb (GD 11.5 or 13) was not altered
with thalidomide treatment and was similar to control
limb bud patterns of Fgf-10 localization and expres-
sion. Rat limb morphology, in both size and symmetry,
was not affected on either GD 11.5 or GD 13 with
thalidomide treatment and appeared similar to control
embryonic limbs.
Control rat limb buds from GD 11.5 and 13 embryos
showed localization and expression of Twist not only in
the limb bud PZ but also throughout the entire limb
bud mesenchymal field. Similar to Fgf-8 and Fgf-10
expression, no significant alterations in Twist expres-
sion were observed in GD 11.5 or 13 limb buds from rat
embryos receiving thalidomide treatment and ap-
peared identical to control limb buds (Figs. 3, 4). Sim-
ilar to Fgf-10 probed embryos, rat limb morphology was
not affected by thalidomide treatment and seemed
equivalent in size, shape, and symmetry.
Control rat embryos showed Fgf-8 localization and
expression in the AER on GD 11.5 and 13 across the
limb bud periphery, the normal region for Fgf-8 expres-
sion (Fig. 5). Thalidomide treatment did not affect the
expression or localization of Fgf-8 in the AER on either
GD 11.5 or 13 (Figs. 3, 4). No abnormalities were ob-
served in rat limb buds treated with thalidomide com-
pared with control rat limb buds.
The expression and localization of Fgf-10 in control
rabbit embryos was normal in GD 10 limbs confined to
the region of the presumptive PZ (Fig. 5) Fgf-10 local-
ization was more easily assessed in rabbit limb buds
that had progressed further in development on GD 11
and 12. Thalidomide treatment caused a decrease in
expression of Fgf-10 in rabbit limb buds from GD 10,
11, and 12 embryos. In younger embryos (GD 10 and
11), Fgf-10 expression was greatly attenuated and al-
most undetectable. Expression of Fgf-10 in GD 12 em-
bryos was restricted to the more proximal and lateral
portions of the limb and was not found in the distal tip
of the limb bud, the region of the PZ, where it is notably
absent. Although difficult to evaluate on GD 10, GD 11,
Fig. 3. In situ hybridization of control and thalidomide-treated rat
embryos for Fgf-10, Twist, and Fgf-8 expression in the gestation day
(GD) 11.5 rat limb bud. Thalidomide treatment had no effect on the
expression of Fgf-10, Twist, and Fgf-8 compared with control. Arrows
denote the limb and regions where Fgf-10, Twist, and Fgf-8 expression
normally occurs.
Fig. 4. In situ hybridization of control and thalidomide-treated rat
embryos for Fgf-10, Twist, and Fgf-8 expression in the gestation day
(GD) 13 rat limb bud. Thalidomide treatment had no effect on the expres-
sion of Fgf-10, Twist, and Fgf-8 compared with control. Arrows denote
regions where Twist expression normally occurs.
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and GD 12, rabbit embryos treated with thalidomide
appeared asymmetrical and malformed. On GD 12,
thalidomide-treated limb buds were notably smaller,
and asymmetrical regions of these embryonic limbs
coincided with areas of decreased Fgf-10 expression.
Control rabbit embryonic limb buds did not share these
same malformations but appeared normal in both size
and shape.
Control rabbit limb bud expression of Twist was eas-
ily detectable and was uniformly expressed within the
normal boundaries of the developing PZ in GD 10 and
the established PZ in GD 11 and 12 embryos (Fig. 6).
Thalidomide treatment decreased Twist expression in
GD 10 rabbit embryonic limbs but, unlike Fgf-10 ex-
pression, was reduced and not entirely eliminated. GD
11 rabbit embryonic limbs showed expression patterns
similar to the previous gestational day for which Twist
was not inhibited but merely reduced. Twist expression
was generally reduced in GD 12 embryonic limbs from
thalidomide treatment but showed some areas in the
more proximal, lateral aspects where expression was
still robust. However, Twist expression in limb buds
from GD 12 rabbit embryos was absent in the PZ.
Thalidomide-treated rabbit embryonic limbs (GD 11
and 12) were generally smaller and had abnormal mor-
phology. The most distal tip of thalidomide-treated
limbs were not round and appeared to be stunted,
especially in the area where Twist expression was ab-
sent. Rabbit control embryonic limb bud expression of
Twist appeared normal.
Control rabbit limb buds from GD 10 embryos
showed Fgf-8 expression and localization in the region
of the presumptive AER (Fig. 7) and was even more
distinguishable in GD 12 rabbit embryonic limbs. Fgf-8
expression was not detectable in GD 10 rabbit embry-
onic limbs. GD 12 rabbit embryonic limbs showed nor-
mal distribution of Fgf-8 expression on the anterior
portion of the limb only, but Fgf-8 expression was
markedly decreased in the posterior portion of the
Fig. 5. In situ hybridization of control, thalidomide-treated, and tha-
lidomide -phenyl-N-t-butylnitrone (PBN) rabbit embryos for Fgf-10
expression in the gestation day (GD) 10–12 rabbit limb bud. Thalidomide
greatly reduced the expression of Fgf-10 at each stage of limb develop-
ment. However, gene expression was not affected in embryos that re-
ceived both thalidomide and the free radical trapping agent, PBN. Loss of
normal limb morphology is evident in GD 12 embryos treated with tha-
lidomide where the outer most portion of the limb is not uniformly devel-
oped. Arrows denote regions where Fgf-10 expression normally occurs.
Fig. 6. In situ hybridization of control, thalidomide-treated, and -
phenyl-N-t-butylnitrone (PBN) rabbit embryos for Twist expression in the
gestation day (GD) 10–12 rabbit limb bud. Thalidomide greatly reduced
the expression of Twist at each stage of limb development. However,
gene expression was not affected in embryos that received both thalid-
omide and PBN. Loss of normal limb morphology is evident in GD 12
embryos treated with thalidomide where limb bud paddles have failed to
develop normally and Twist expression is absent. Arrows denote regions
where Twist expression normally occurs.
Fig. 7. In situ hybridization of control, thalidomide-treated, and -
phenyl-N-t-butylnitrone (PBN) rabbit embryos for Fgf-8 expression in the
gestation day (GD) 10–12 rabbit limb bud. Thalidomide greatly reduced
the expression of Fgf-8 at each stage of limb development. However,
gene expression was not affected in embryos that received both thalid-
omide and PBN. Loss of Fgf-8 expression is most notable in the region of
the zone of polarizing activity. Arrows denote regions where Fgf-8 ex-
pression normally occurs.
190 HANSEN ET AL.
limb. Limb morphology on GD 12 in rabbit embryonic
limb buds were relatively symmetrical in areas were
Fgf-8 was expressed. However, on the posterior aspect
of the developing limb (GD 12), the area of the pre-
sumptive ZPA, the limb loses its normal shape, appears
to be stunted, and does not share the same symmetry
with regions that express Fgf-8.
Cotreatment with PBN restores the expression of
Fgf-10 in the GD 10 rabbit limb buds in the presump-
tive PZ (Fig. 5). The pattern of Fgf-10 expression in GD
12 rabbit limb buds appeared similar to control limb
buds, and expression was reestablished in area of the
PZ. The patterns of localization and expression of Twist
were also preserved in rabbit limb buds with the co-
treatment of thalidomide and PBN (Fig. 6). In rabbit
embryos that received both thalidomide and PBN,
Fgf-8 expression in the limb bud AER was restored to
control patterns of localization and expression of Fgf-8
(Fig. 7). Limb morphology in GD 12 rabbit embryonic
limbs was restored and was comparable with control
rabbit limb buds.
DISCUSSION
The disturbances observed in GSH concentration,
redox state, and spatial distribution caused by thalid-
omide exposure are consistent with the type of changes
in cellular environment that would result in misregu-
lation of NF-B–mediated gene expression. HgO histo-
chemistry identifies regions of GSH localization that
show a loss of staining only in the PZ of the sensitive
rabbit limb after in utero exposure to thalidomide. The
reasons for selective depletion of GSH in the rabbit
limb PZ are not entirely understood. Factors related to
selectivity may include preferential sequestration or
accumulation of thalidomide in PZ cells, increased
rates of bioactivation and/or protein binding, or insuf-
ficient GSH restoration capacity. Schmahl and cowork-
ers (1996) used radiolabeled EM12, a highly terato-
genic thalidomide derivative, and whole-mount
autoradiography to show differences in patterns of dis-
tribution between the sensitive (marmoset) and resis-
tant (mouse and rat) species. Sensitive species were
found to preferentially accumulate EM12 in the limb
and neural tube, whereas insensitive species showed
no such preferential distribution and deposition. The
rabbit may possess similar pharmacokinetic properties
that allow for selective accumulation of thalidomide in
the limb, although this finding has not been demon-
strated and mechanisms have not been described. With
regard to species differences in thalidomide metabo-
lism and biotransformation, very little is known about
how thalidomide is metabolized or the identity of the
proximal reactive species. Arlen and Wells (1996) have
suggested that enzymes, such as prostaglandin H syn-
thase (PHS), may be important in thalidomide-induced
oxidative stress, because cotreatment with the irre-
versible PHS inhibitor, acetylsalicylic acid, in rabbits
significantly decreased limb anomalies as well as post-
partum fetal lethality. Differences in PHS activity or
distribution in the rat and rabbit limbs have yet to be
reported.
The PZ region sensitive to GSH depletion by thalid-
omide is believed to initiate the primary organization
and regulation of proximodistal outgrowth of the limb
by stimulating the production of growth factors,
through the activation and binding of NF-B. It is also
the site for the establishment of the feedback loop
between Fgf-10 in the PZ and Fgf-8 in the AER (Cross-
ley et al., 1996; Martin, 1998). Fgf-10 deletions prevent
limb outgrowth in mice, resulting in complete amelia, a
known effect of thalidomide in humans, and suggesting
that Fgf-10 may be involved in thalidomide teratogen-
esis (Kato and Sekine, 1999).
Thalidomide, which produces an entire spectrum of
limb reduction defects in sensitive species, including
human, could be interfering with these critical growth
pathways. Interference with NF-B activation causes
limb defects in both mouse and chick models, for which
Twist, Shh, and Fgf-8 expression were down-regulated.
These experiments provide the basis for our current
understanding of NF-B’s involvement in limb out-
growth pathways (Bushdid et al., 1998; Kangae et al.,
1998). TWIST mutations in humans result in selective
limb malformations and suggest another possible tar-
get for thalidomide-induced loss of gene expression
(Paznekas et al., 1998; Rice et al., 2000). Sonic hedge-
hog (Shh), a critical component of limb patterning, was
shown to be affected by the disruption of NF-B signal-
ing pathways in the limb resulting in complete inhibi-
tion of its expression (Bushdid et al., 1998; Kangae et
al., 1998). Recent studies where Shh was deleted in a
transgenic mouse showed that expression of Fgf-8 was
undetectable in the posterior aspect of the AER,
whereas the remainder of the AER was unaffected
(Kraus et al., 2001). These same manifestations were
evident in rabbit embryos treated with thalidomide
(Fig. 7) and suggests a possible relationship between
Shh expression and thalidomide-induced limb defects.
To evaluate the effects of thalidomide on NF-B/
DNA binding, transfection of NF-B–dependent re-
porters allowed for comparisons in both rat and rabbit
LBCs. Other investigators have used electromobility
shift assays (EMSA) to determine the effects of differ-
ent chemicals on NF-B activation. However, EMSAs
are designed to measure NF-B activation (NF-B/
I-B dissociation) and translocation, and although the
assay does measure NF-B binding, binding occurs
under ideal conditions in vitro with isolated nuclear
extracts. Drug-induced changes in nuclear redox envi-
ronment that could alter DNA binding in situ may not
be reflected in an EMSA. By using transfection of NF-
B–dependent reporters and cotreating with tetra-
decanoylphorbol acetate (TPA), to completely activate
NF-B, we were able to determine effects of thalido-
mide on NF-B/DNA binding in intact cells. Diamide,
an oxidant and known inhibitor NF-B /DNA binding,
showed a significant decrease in reporter expression in
both transfected rat and rabbit LBCs but showed a
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greater effect in the rabbit. Again these differences
may be because rabbit conceptuses contain inherently
less GSH and cysteine than rat conceptuses (Hansen et
al., 1999). Unlike diamide, thalidomide produced an
effect only in rabbit LBCs. Diamide effects on NF-B/
DNA binding correlate with the species that has lower
GSH and greater sensitivity to agents that elicit oxi-
dative stress (Hansen et al., 2001b, 2002).
Thalidomide-induced production of ROS can be effec-
tively reversed by the addition of NAC and PBN to the
culture media, suggesting that thalidomide (or a me-
tabolite) induces oxidative stress, and it is by oxidative
stress that misregulation of NF-B/DNA binding oc-
curs. Previous work has demonstrated the ability of
ROS-induced redox potential changes to profoundly ef-
fect NF-B/DNA binding, decreasing NF-B’s ability to
successfully transactivate genes (Sun and Oberley,
1996; Galter et al., 1994; Beuerle and Henkle, 1994;
Matthews and Hay, 1995; Baldwin, 1996; Sen and
Packer, 1996; Flohe et al., 1997; Ginn-Pease and
Whisler, 1998).
Other proposed hypotheses of thalidomide teratogen-
esis do not provide a complete rationale for the incom-
plete penetrance of thalidomide-induced limb reduc-
tion defects, which occur in 30% of rabbit fetuses with
doses of 250 mg/kg per day on GD 8 and 9 (Schardein,
1993). As a generalization, several factors related to
the regulation of intracellular redox status may affect
NF-B binding and its dynamic role in regulating gene
expression. In the generation of ROS and oxidative
stress, treatment with toxicants can result in the re-
duction of the expression of redox-sensitive dependent
genes and, in most cases, does not produce complete
inhibition of gene expression. Elimination of ROS and
oxidative stress, as observed with cotreatment with
NAC and PBN, confirm intracellular redox status to
play a critical role in thalidomide-induced modulation
of NF-B activity. Therefore, thalidomide-induced
changes in the redox environment must be sustained
and sufficient to decrease the activity of NF-B to a
level where subsequent loss of gene expression compro-
mises the Fgf-10/Fgf-8 feedback loop and produces limb
dysmorphogenesis. The above outlined NF-B–medi-
ated mechanism can account for both the specific set of
terata as well as differences in terata penetrance.
This study outlines a specific mechanism by which
limb reduction but not limb patterning is affected by
thalidomide. Unlike previously proposed hypotheses,
the hypothesis that thalidomide induces redox changes
responsible for NF-B–dependent limb bud outgrowth
gene misregulation is consistent across sensitive and
insensitive species and provides a solid rationale for
common thalidomide-induced terata. In addition, these
data suggest that misregulation of other redox-sensi-
tive transcription factors that may serve as a novel
mechanism of other teratogens that cause oxidative
stress and elicit a distinct set of malformations.
EXPERIMENTAL PROCEDURES
Reagents
Thalidomide was purchased from Toronto Research
Chemicals (Toronto, Ontario, Canada). HgO, NAC,
PBN, and TPA were purchased from Sigma (St. Louis,
MO). Hank’s balanced salt solution (HBSS) was ac-
quired from Life Sciences (Grand Island, NY). CMRL-
1066 culturing media was purchased from Gibco Life
Technologies (Grand Island, NY). Nu-serum was pur-
chased from Becton-Dickinson (Cincinnati, OH). All
other reagents were obtained from common commer-
cial sources.
Animals
Primagravida Sprague-Dawley rats were obtained
from the Toxicology Program Small Animal Facility,
University of Michigan (Ann Arbor, MI) on GD 6–9.
Day 0 was determined by a sperm-positive vaginal
smear on the morning after copulation. Pregnant rats
were maintained on a 12-hr light/ 12-hr dark cycle
until explantation. Food and water were given ad libi-
tum.
Primagravida New Zealand White rabbits (5.5–7
months old) were purchased from Covance Research
Products, Inc. (Kalamazoo, MI). Females were naturally
mated with males of the same strain (with the day of
copulation assigned as GD 0 at the supplier’s facility),
shipped on GD 1, and then allowed to acclimate to the
new environment until explantation. Food and water
were also given ad libitum.
Mercury Orange Histochemistry
Rabbits were treated between GD 8 and 12 by means
of oral gavage with 70 mg thalidomide/kg per day, a
dose known to elicit limb reduction defects in New
Zealand White rabbit embryos (Schardein, 1993). On
GD 12, embryos were removed and fixed in OTC freez-
ing medium (Miles, Inc., Diagnostics Div., Elkhart,
NJ), snap-frozen in liquid nitrogen, and stored at
70°C until sectioning.
Rats were treated between GD 9–13 by means of oral
gavage with 300 mg thalidomide/kg per day. On GD 13,
embryos were removed and fixed in OTC freezing me-
dium, snap-frozen in liquid nitrogen, and stored at
70°C until sectioning. Mercury orange staining tech-
niques used are as described by Philbert and coworkers
(1991). After treatment with thalidomide in vivo and
storage, samples were cryosectioned (10 m thick),
placed on a coverslip, and stained in anhydrous toluene
containing mercury orange (50 M) for 5 min. Slides
were cleared with two subsequent washes of anhydrous
alcohol followed by two washes in dried toluene and
mounted in Permount. Slides were stored at 20°C for
at least 24 hr before visualization by using fluorescence
microscopy at an excitation of 488 nm and an emission
of 530 nm.
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Transfection of Limb Bud Cells With
pNF-B-d2EGFP
The vector, pNF-B-d2EGFP (Clontech, Palo Alto,
CA), contains four kappa B binding sites in its pro-
moter. Occupation of these sites results in the induc-
tion of expression of EGFP, green fluorescent protein.
Limb bud cells were isolated from rat (GD 13) and
rabbit (GD 12) embryos. On GD 13 in rats and GD 12 in
rabbits, embryos were removed from rats and rabbits
and placed in warmed HBSS. By using a stereo-dissec-
tion microscope, both the forelimbs and hindlimbs were
removed from each embryo, and each respective spe-
cies’ limbs were pooled together. Limbs were washed
twice in HBSS and placed in a sterile microcentrifuge
tube containing calcium/magnesium-free phosphate-
buffered saline (CMF-PBS) supplemented with 0.1%
trypsin (w/v) and 0.1% ethylenediaminetetraacetic acid
(w/v). Samples were placed in a water bath and heated
to 37°C for 18–20 min or until cells were sufficiently
dissociated. Tubes were inverted two to three times
during dissociation and were gently pipetted in and out
at the end of the trypsinization to produce a single cell
suspension. Nu-serum was added to the suspension to
stop the dissociation, and the cells were centrifuged for
5 min at 1,000 rpm at 5°C after which the supernatant
was removed and discarded. Cells were resuspended in
CMRL-1066 media that had been supplemented with
10% Nu-serum (v/v) and antibiotics (penicillin and
streptomycin). The suspension was filtered by using a
40-m nylon-filtered cell strainer to remove any undis-
sociated cells. Single cells were then resuspended to a
final concentration of 2.0 	 107 cells per ml. Aliquots
consisting of 1.0 	 106 cells were put into wells con-
taining 3.0 ml of medium in a 6-well plate. Cultures
were maintained in a humidified incubator at 37°C in
an atmosphere of 95% O2 per 5% CO2 (v/v), allowing
the cells to attach to the plate surface. These conditions
are found to promote the maintenance and viability of
LBCs (Kistler and Howard, 1987). Cells were cultured
for 24–48 hr before transfection. pNF-B-d2EGFP was
transfected into LBCs as directed by the supplier of
Clonfectin, a liposomal transfection system, purchased
from Clontech. A LacZ transfection was also performed
to assess transfection efficiency. After transfection (24
hr), cells were treated with thalidomide (100 M) and
diamide (100 M), which is known to decrease NF-B
binding (Toledano and Leonard, 1991), as a positive
control. Two hours after the initial thalidomide/dia-
mide treatment, cultures were treated with TPA, a
phorbol ester that stimulates the dissociation of the
NF-B/ I-B complex. Some cultures were pretreated (4
hr) with NAC, a precursor to GSH synthesis, or PBN, a
free radical trapping agent. After 24 hr of treatment,
cultures were washed with PBS and pelleted in micro-
centrifuge tubes after which the supernatant was re-
moved. The pellet was washed, resuspended, and pel-
leted two more times in PBS after which it was finally
resuspended in sonication buffer (50 mM NaH2PO4, 10
mM Tris-HCl, 200 mM NaCl [pH 8.0]). Samples were
freeze/thawed in a dry ice/ethanol bath five times, vor-
texed for 1 min, and placed on ice for 1 min. Samples
were pipetted in and out of 18-gauge needles several
times and then transferred to a microcentrifuge tube
and centrifuged for 5 min at 4°C. Supernatants were
removed and assayed for GFP in a fluorometer at an
excitation of 488 nm and an emission of 510 nm.
In Situ Hybridization
Probes for mouse Fgf-8 were provided by Dr. Siew-
Ging Gong (University of Michigan), mouse Fgf-10 by
Dr. Gail Martin (University of California, San Fran-
cisco, CA), and chick Twist by Dr. Sumihare Noji (Uni-
versity of Tokushima, Japan).
Primagravida rats were treated by gavage with 400
mg thalidomide/kg per day on GD 9 and 10. Embryos
were removed on GD 11.5 and 13, fixed in 3.7% para-
formaldehyde in PBS overnight, then prepared for in
situ hybridization by washes in methanol.
Primagravida rabbits were treated by gavage with
400 mg thalidomide/kg per day on GD 8 and 9, the
sensitive period for limb reduction defects in the New
Zealand White rabbit (Fabro, 1981). Embryos were re-
moved on GD 10, 11, and 12 and fixed in 3.7% parafor-
maldehyde in PBS overnight then prepared for in situ
hybridization by washes in methanol. Further prepa-
ration and protocols for whole-mount in situ hybridiza-
tion that were used in this study are described in detail
by Wilkinson (1992).
Some rabbits were pretreated with 40 mg PBN/kg
per day by means of intravenous injection before the
thalidomide oral gavage doses. Embryos from these
rabbits were removed, fixed in 3.7% paraformaldehyde,
and processed for in situ hybridization in an identical
manner as those embryos receiving thalidomide only.
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